GE HealthCare Q2: 5.7% Revenue Growth, Tariff Refunds Lift Margins, but PCS Stumbles
GEHC sits 15% above its 52-week low of $58.75.
Summary
Second-quarter revenue reached $5.3 billion, up 5.7%, with tariff refunds bolstering profits. However, losses in the PCS segment and lingering legal and leadership issues cloud the outlook.
Key Events · Earnings and Guidance · GEHC
-
Revenue Growth Led by AIS and PDx
Total revenues rose 5.7% to $5.3 billion, powered by a 7.9% jump in Advanced Imaging Solutions and a 15.6% surge in Pharmaceutical Diagnostics. Patient Care Solutions, however, fell 13.3% as operational and fulfillment headwinds persisted.
-
Tariff Refunds Boost Margins
A $106 million pre-tax benefit from IEEPA tariff refunds—with $107 million already in cash and a $38 million receivable—helped offset incremental tariff costs and lifted gross margin.
-
PCS Segment Swings to Loss
Patient Care Solutions swung to a Segment EBIT loss of $26 million, a sharp reversal from the $60 million profit a year ago, as volume declines and cost inflation bit.
-
Segment Realignment
The company merged its Imaging and Advanced Visualization Solutions businesses into a new Advanced Imaging Solutions segment, restating historical results accordingly.
Analysis · GEHC · Industrial Applications And Services
GE HealthCare posted a solid second quarter, with revenue climbing 5.7% to $5.3 billion on the back of strength in Advanced Imaging Solutions and Pharmaceutical Diagnostics. Margins got a lift from a $106 million pre-tax benefit tied to tariff refunds, yet the Patient Care Solutions segment swung to an operating loss as operational challenges took their toll. The period also brought a segment realignment and ongoing share buybacks, while a CFO transition and a securities fraud investigation add a layer of uncertainty.
At the time of this filing, GEHC was trading at $67.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $29.2B. The 52-week trading range was $58.75 to $89.77. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.